Hwabao WP CSI Pharmaceuticals ETF (562050) News

Express News | Hang Seng Yinhua CSI Innovative Drugs Industry ETF (159316) “sucked” 0.33 billion yuan last week. The latest scale was nearly 1.6 billion yuan, a record high

BreakingsAug 25, 2025 20:44

ETF Market Review | AI computing power continues to be strong, the communications ETF rises by 4%, while Hong Kong's innovative pharmaceuticals experience a pullback, with the Hong Kong innovative pharmaceuticals ETF fund declining by 3%.

Gelonghui, August 19 | All three major indices of the A-share market closed lower. By the end of trading, the Shanghai Composite Index fell by 0.02%, the Shenzhen Component Index dropped by 0.12%, and the ChiNext Index decreased by 0.17%. The Beijing Stock Exchange 50 Index rose by 1.27%, reaching a new high. The market has seen over 20 trillion yuan in transaction volume for the fifth consecutive day, with total trading volume in the Shanghai, Shenzhen, and Beijing markets amounting to 26,407 billion yuan, a decrease of 1,685 billion yuan from the previous day. Over 2,900 individual stocks in the market rose. The concepts of CPO and consumer electronics continue to be hot, with Industrial Fulian reaching its daily limit and approaching a market capitalization of 1 trillion yuan. The liquor and robotics sectors showed active performance; however, large financial institutions generally took a breather, alongside the concepts of PEEK materials, lithography machines, and military information technology.

Gelonghui FinanceAug 19, 2025 15:15

Express News | The Hang Seng Innovation Pharmaceutical ETF (159316) has attracted significant inflows for four consecutive trading days, setting new record highs in its asset size.

BreakingsAug 13, 2025 20:45

The Shanghai Composite Index rose above 3666 points, aiming for a seventh consecutive day of gains! The Innovative Medicine ETF (517380) by Tianhong has seen strong inflows for 12 consecutive days, while the Aerospace and Defense ETF (159241) by Tianhong

Gelonghui, August 12th | Buoyed by the continued extension of tariffs between China and the U.S., the Shanghai Composite Index closed up 0.51% at 3,666.33 points at midday, aiming for a seventh consecutive day of gains and continuing to set new highs for the year. The innovative pharmaceuticals and aerospace defense sectors saw the most significant pullbacks, with the Tianhong Innovative Pharmaceuticals ETF (517380) down 0.78% and the Tianhong Aerospace Defense ETF (159241) down 2.1%. Despite these declines, these two ETFs saw substantial buying interest, with the Tianhong Innovative Pharmaceuticals ETF (517380) receiving net subscriptions for 12 consecutive days, totaling RMB 187 million.

Gelonghui FinanceAug 12, 2025 11:37

Express News | The Index closed in positive territory, with the new compilation methodology taking effect today. The Yinhua CSI Innovative Drugs Industry ETF (159316) saw a net subscription of 10 million units for the day.

BreakingsAug 11, 2025 15:48

Express News | The purity of innovative drugs is fully maximized, with the Yinhua CSI Innovative Drugs Industry ETF (159316) symbol Index undergoing a comprehensive upgrade.

BreakingsAug 11, 2025 10:27

Love health, love pharmaceuticals; Huabao Funds launches another off-exchange index fund, the 'Pharmaceutical ETF Link Fund (024985/024986)'.

The only domestic 'Pharmaceutical ETF (562050)' established and listed in the second quarter of this year has won the favor of investors with its impressive performance and good net asset value. On Friday, August 8th, the Pharmaceutical ETF Linked Funds (Class A: 024985; Class C: 024986) were exclusively launched for off-exchange investors. Investors who are highly enthusiastic about the long-term and lucrative pharmaceutical sector can pay attention to the fund's issuance dynamics and product features. In short, the Pharmaceutical ETF Linked Funds mainly invest in the Pharmaceutical ETF (562050), thereby achieving the tracking of the CSI Pharmaceutical Index, providing a one-stop solution.

China InvestorsAug 8, 2025 09:17

Express News | Policy support for innovation in the pharmaceutical industry is increasing; consider the investment value of the Yinhua CSI Innovative Drugs Industry ETF (159316) and the CSI Health Care ETF (512010).

BreakingsAug 7, 2025 20:19

Express News | The Yinhua CSI Innovative Drugs Industry ETF (159316) has continuously attracted significant inflows, with its latest size exceeding RMB 1 billion, reaching a record high.

BreakingsAug 6, 2025 20:19

ETF Review | The innovative drugs sector in Hong Kong stocks was strong throughout the day, with the Yinhua CSI Innovative Drugs Industry ETF and the Hang Seng Innovative Drug ETF rising by 3%.

Gelonghui, August 5 | The three major A-share indices collectively closed higher. As of the close, the Shanghai Composite Index rose 0.96% to 3,617.6 points, setting a new high for the period. The Shenzhen Component Index gained 0.59%, and the GEM Index increased by 0.39%. The SSE Financials Sector Equal Weight Index rose 0.25%. The total trading volume in the Shanghai, Shenzhen, and Beijing markets reached RMB 1.6158 trillion, an increase of RMB 97.6 billion from the previous day. Over 3,900 stocks across the two markets rose. In terms of sectors, the PEEK Material Concept saw a full-scale rally, while the High-Speed Copper Connection and Consumer Electronics Sectors performed notably well. The large financial sector and other weighty sectors surged in the afternoon. The Cloud Computing and Medical Sectors experienced slight declines. In the ETF market, the Hong Kong Biotech Sector was strong throughout the day.

Gelonghui FinanceAug 5, 2025 15:12

Express News | The innovative drugs sector in the Hong Kong stock market was active in early trading, with the Yinhua CSI Innovative Drugs Industry ETF (159316) receiving a net subscription of 35 million units.

BreakingsAug 5, 2025 10:57

Express News | Enhanced policy support for innovative drugs has led to a counter-trend rise in the related sector this week, with the Yinhua CSI Innovative Drugs Industry ETF (159316) and other funds providing opportunities to capitalize on the industry's development.

BreakingsAug 1, 2025 19:51

Express News | The global value of innovative drugs has been recognized, and the Hang Seng Yinhua CSI Innovative Drugs Industry ETF (159316) has continuously “sucked in gold” and reached a record high in scale

BreakingsJul 30, 2025 21:19

Express News | The intelligent transformation of the pharmaceutical industry, with the E Fund Artificial Intelligence ETF (159819) and the Yinhua CSI Innovative Drugs Industry ETF (159316), among others, are helping to position for development opportunities in the secto

BreakingsJul 30, 2025 21:08

A-shares staged a V-shaped rebound, with funds aggressively buying the Tianhong Aerospace ETF (159241) and the Yinhua CSI Innovative Drugs Industry ETF (517380) attracting inflows for three consecutive days.

Gelonghui, July 30 | A-shares experienced a deep V-shaped rebound in the closing minutes, with the Shanghai Composite Index turning from a 0.41% decline to a 0.26% gain. The biopharmaceutical sector's decline narrowed from 1.29% to 0.23%. The declines in the Hang Seng CSI HK Innovation Medicine 50 Index and the Guozheng Aerospace Index also narrowed. As of the time of writing, the Guotai CSI BIOMEDICINE ETF (159859), Yinhua CSI Innovative Drugs Industry ETF (517380), and Tianhong Aerospace ETF (159241) were down 0.23%, 1.69%, and 1.25%, respectively. On the news front, the Political Bureau of the Central Committee of the Communist Party of China held a meeting on July 30, during which it was pointed out that efforts should be made to enhance the attractiveness of domestic Capital Markets.

Gelonghui FinanceJul 30, 2025 14:54

Express News | The Yinhua CSI Innovative Drugs Industry ETF saw a 7% premium during intraday trading, prompting the fund company to issue an urgent risk warning.

BreakingsJul 30, 2025 13:48

Express News | The Index surged nearly 4%, with the CSI Health Care ETF (513200) and others aiding in the layout of leading healthcare companies in the Hong Kong market.

BreakingsJul 29, 2025 20:38

The Yinhua CSI Innovative Drugs Industry ETF is dominating the screen! Is there still an opportunity to enter the market?

Recently, the second-quarter performance of Funds has been gradually released, with ETFs tracking the CNI Biomedicine Index dominating the screen! Data shows that in the first half of this year, the top 17 ROIs among ETFs were all products tracking the CNI Biomedicine Index. Industry insiders have pointed out that, driven by both industrial catalysts and policy support, the long-term investment value of the innovative drug sector is becoming evident. Currently, the valuation expectations for Chinese innovative drugs are on the rise, and in the long term, it may still be a main investment theme. (Data source: Wind, 2025.1.1-2025.6.30; historical fund performance does not indicate future results; reference: 21st Century Business Herald, 'Innovative Drugs Lead the Hong Kong Stock Market')

lanjinger.comJul 29, 2025 16:23

Midday ETF Review | The innovative drugs sector continues to surge, with the Yinhua CSI Innovative Drugs Industry ETF and the Guotai CSI Innovative Drugs Industry ETF rising by 4.56% and 4.26%, respectively.

Gelonghui, July 29 | The three major A-share indices experienced narrow-range fluctuations. As of the midday close, the Shanghai Composite Index fell by 0.08%, the Shenzhen Component Index fell by 0.04%, and the GEM Index rose by 0.92%. The Beijing Stock Exchange 50 Index fell by 0.04%. The total trading volume of the Shanghai, Shenzhen, and Beijing stock exchanges was RMB 1.1459 trillion, an increase of RMB 7.1 billion from the previous day. Over 3,800 stocks in the two markets declined. In terms of sectors, the CRO, PET Copper Foil, and semiconductor sectors saw gains, while the Glyphosate and insurance sectors experienced adjustments. In the ETF sector, the innovative drug sector continued to surge, with the Yinhua CSI Innovative Drugs Industry ETF, Guotai CSI Innovative Drugs Industry ETF, and Huabao Fund HKEX Innovative Drugs ETF rising by 4.56%.

Gelonghui FinanceJul 29, 2025 11:47

The Yinhua CSI Innovative Drugs Industry ETF (517380) surged 4.56%, leading the All Market with the highest gain.

Gelonghui, July 29 | The innovative drugs sector continued to show strength today, with component stocks Pharma Block Sciences, TIGERMED, Jiuzhou Pharmaceuticals, and WUXI APPTEC rising by 17.45%, 13.46%, 10%, and 9.96% respectively. This performance drove the Yinhua CSI Innovative Drugs Industry ETF (517380) to surge by 4.56% at midday, ranking first in the All Market pharmaceutical ETFs, aiming for a fifth consecutive day of gains, with an increase of nearly 60% since its low point on April 10. In terms of news, the pharmaceutical sector continues to receive multiple bullish catalysts: ① Chinese innovative drugs are setting new records for overseas expansion, with Hengrui Pharmaceuticals and GSK reaching a licensing agreement worth up to $12 billion, following yesterday's announcement.

Gelonghui FinanceJul 29, 2025 11:36